株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

子宮頸癌:パイプライン分析

Cervical Cancer - Pipeline Review, H2 2016

発行 Global Markets Direct 商品コード 232853
出版日 ページ情報 英文 472 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.58円で換算しております。
Back to Top
子宮頸癌:パイプライン分析 Cervical Cancer - Pipeline Review, H2 2016
出版日: 2016年11月23日 ページ情報: 英文 472 Pages
概要

子宮頸癌は、ヒトパピローマウイルスが原因であるものが多く、初期における自覚症状はほとんどありません。症状は不正出血、性交時や閉経後、月経期間以外の出血または帯下、通常よりも長期または大量の月経出血などであり、治療には外科的手術、放射線治療、化学療法などの併用療法が用いられます。

当レポートでは、子宮頸癌に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

目次

イントロダクション

子宮頸癌の概要

治療薬の開発

  • パイプライン製品:概要
  • パイプライン製品:比較分析

開発中の治療薬:企業別

調査中の治療薬:大学/研究所別

パイプライン製品の概要

  • 後期段階の製品
  • 臨床段階の製品
  • 初期段階の製品

開発中の製品:企業別

調査中の製品:大学/研究機関別

治療薬の開発に従事している企業

  • 3SBio Inc.
  • Admedus Ltd
  • Advaxis, Inc.
  • Advenchen Laboratories, LLC
  • AnGes MG, Inc.
  • Antigen Express, Inc.
  • Arbor Vita Corporation
  • ArQule, Inc.
  • AstraZeneca Plc
  • AVEO Pharmaceuticals, Inc.
  • Azaya Therapeutics, Inc.
  • Blirt S.A.
  • Bristol-Myers Squibb Company
  • Cancer Research Technology Limited
  • Cellceutix Corporation
  • Chong Kun Dang Pharmaceutical Corp.
  • Coherus BioSciences, Inc.
  • Critical Outcome Technologies Inc.
  • CZ BioMed Corp
  • DelMar Pharmaceuticals, Inc.
  • Dr. Reddy's Laboratories Limited
  • EirGenix Inc.
  • エーザイ
  • Eureka Therapeutics, Inc
  • EyeGene, Inc. 63
  • F. Hoffmann-La Roche Ltd.
  • Formune S.L.
  • Genexine, Inc.
  • Genmab A/S
  • Genor BioPharma Co., Ltd.
  • Genticel S.A.
  • GlaxoSmithKline Plc
  • Immunovaccine, Inc.
  • ISA Pharmaceuticals B.V.
  • Johnson & Johnson
  • Karyopharm Therapeutics, Inc.
  • Kite Pharma, Inc.
  • LondonPharma Ltd
  • Mabion SA . 77
  • MedImmune, LLC
  • MEI Pharma, Inc.
  • Mundipharma International Ltd
  • Mycenax Biotech Inc.
  • Nanotherapeutics, Inc.
  • Nektar Therapeutics
  • Novartis AG
  • Oncobiologics, Inc.
  • 小野薬品工業 .
  • Oryx GmbH & Co. KG
  • 大塚ホールディングス
  • PDS Biotechnology Corporation
  • Pfizer Inc.
  • Psicofarma S.A. de C.V.
  • Rexahn Pharmaceuticals, Inc.
  • Samyang Holdings Corporation
  • Sanofi
  • Savoy Pharmaceuticals, Inc.
  • Seattle Genetics, Inc.
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
  • Shantha Biotechnics Limited
  • Sirnaomics, Inc.
  • Sun Pharma Advanced Research Company Ltd.
  • 大鵬薬品工業
  • Theravectys SA
  • Tomegavax, Inc.
  • UbiVac, LLC
  • Vaccibody AS
  • VLPbio
  • Zeria Pharmaceutical Co., Ltd.
  • Zydus Cadila Healthcare Limited

治療薬の評価

  • 単独療法の製品
  • 併用療法の製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤のプロファイル

パイプライン製品の最新動向

休止中のプロジェクト

開発が中止された製品

製品開発のマイルストーン

  • 注目情報とプレスリリース

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8700IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cervical Cancer - Pipeline Review, H2 2016, provides an overview of the Cervical Cancer (Oncology) pipeline landscape.

Cervical cancer occurs when abnormal cells on the cervix grow out of control. Most cervical cancer is caused by a virus called human papillomavirus, or HPV. Abnormal cervical cell changes rarely cause symptoms. Symptoms of cervical cancer may include abnormal vaginal bleeding, such as bleeding after sex (vaginal intercourse), bleeding after menopause, bleeding and spotting between periods, and having longer or heavier (menstrual) periods than usual. Treatment options include surgery, radiation therapy, chemotherapy or a combination of methods.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Cervical Cancer - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Cervical Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Cervical Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Cervical Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 5, 20, 29, 1, 39, 3 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 4, 1, 9 and 5 molecules, respectively.Cervical Cancer.

Cervical Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Cervical Cancer (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Cervical Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Cervical Cancer (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Cervical Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Cervical Cancer (Oncology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Cervical Cancer (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Cervical Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents 2
  • List of Tables 8
  • List of Figures 10
  • Introduction 11
  • Global Markets Direct Report Coverage 11
  • Cervical Cancer Overview 12
  • Therapeutics Development 13
  • Pipeline Products for Cervical Cancer - Overview 13
  • Pipeline Products for Cervical Cancer - Comparative Analysis 14
  • Cervical Cancer - Therapeutics under Development by Companies 15
  • Cervical Cancer - Therapeutics under Investigation by Universities/Institutes 21
  • Cervical Cancer - Pipeline Products Glance 22
  • Late Stage Products 22
  • Clinical Stage Products 23
  • Early Stage Products 24
  • Unknown Stage Products 25
  • Cervical Cancer - Products under Development by Companies 26
  • Cervical Cancer - Products under Investigation by Universities/Institutes 33
  • Cervical Cancer - Companies Involved in Therapeutics Development 34
  • Abion Inc 34
  • Admedus Ltd 35
  • Advaxis Inc 36
  • Advenchen Laboratories LLC 37
  • Antigen Express Inc 38
  • Arbor Vita Corp 39
  • ArQule Inc 40
  • AstraZeneca Plc 41
  • AVEO Pharmaceuticals Inc 42
  • Azaya Therapeutics Inc 43
  • Bioleaders Corporation 44
  • Biomics Biotechnologies Co Ltd 45
  • Blirt SA 46
  • Boehringer Ingelheim GmbH 47
  • Bristol-Myers Squibb Company 48
  • Cancer Research Technology Ltd 49
  • Cell Medica Ltd 50
  • Cellceutix Corp 51
  • Coherus BioSciences Inc 52
  • Critical Outcome Technologies Inc 53
  • CZ BioMed Corp 54
  • DelMar Pharmaceuticals, Inc. 55
  • Dr. Reddy's Laboratories Ltd 56
  • EirGenix Inc. 57
  • Eisai Co Ltd 58
  • Etubics Corp 59
  • Eureka Therapeutics Inc 60
  • EyeGene Inc 61
  • F. Hoffmann-La Roche Ltd 62
  • Formune SL 63
  • GamaMabs Pharma SA 64
  • Gene Techno Science Co Ltd 65
  • Genexine Inc 66
  • Genmab A/S 67
  • Genor BioPharma Co Ltd 68
  • Genticel S.A. 69
  • GlaxoSmithKline Plc 70
  • Immune Therapeutics, Inc. 71
  • Immunovaccine Inc 72
  • INSYS Therapeutics Inc 73
  • ISA Pharmaceuticals BV 74
  • Johnson & Johnson 75
  • Karyopharm Therapeutics Inc 76
  • Kite Pharma Inc 77
  • LondonPharma Ltd 78
  • Mabion SA 79
  • Merck & Co Inc 80
  • Mycenax Biotech Inc 81
  • Nanotherapeutics Inc 82
  • Nektar Therapeutics 83
  • Oncobiologics Inc 84
  • Ono Pharmaceutical Co Ltd 85
  • Oryx GmbH & Co KG 86
  • PDS Biotechnology Corp 87
  • Pfizer Inc 88
  • Psicofarma SA de CV 89
  • Rexahn Pharmaceuticals Inc 90
  • Richter Gedeon Nyrt 91
  • Samyang Holdings Corp 92
  • Sanofi 93
  • Savoy Pharmaceuticals, Inc. 94
  • Seattle Genetics Inc 95
  • Selecta Biosciences Inc 96
  • Shantha Biotechnics Ltd 97
  • Sirnaomics Inc 98
  • Sun Pharma Advanced Research Company Ltd 99
  • Taiho Pharmaceutical Co Ltd 100
  • Tessa Therapeutics Pte Ltd 101
  • Theravectys SA 102
  • THEVAX Genetics Vaccine USA Inc 103
  • Tomegavax Inc 104
  • UbiVac LLC 105
  • VLPbio 106
  • Zeria Pharmaceutical Co Ltd 107
  • Zydus Cadila Healthcare Ltd 108
  • Cervical Cancer - Therapeutics Assessment 109
  • Assessment by Monotherapy Products 109
  • Assessment by Combination Products 110
  • Assessment by Target 111
  • Assessment by Mechanism of Action 116
  • Assessment by Route of Administration 121
  • Assessment by Molecule Type 123
  • Drug Profiles 125
  • (hydralazine + valproate magnesium) - Drug Profile 125
  • ABN-301 - Drug Profile 126
  • AEH-10p - Drug Profile 127
  • AL-3818 - Drug Profile 128
  • Ancer - Drug Profile 130
  • Antisense RNAi Oligonucleotide for Cervical Cancer - Drug Profile 131
  • Aptamer to Target HPV E7 Protein for Cervical Cancer - Drug Profile 132
  • ARQ-092 - Drug Profile 133
  • artemether - Drug Profile 136
  • atezolizumab - Drug Profile 138
  • AV-203 - Drug Profile 152
  • AVC-7 - Drug Profile 155
  • axalimogene filolisbac - Drug Profile 156
  • AZD-5363 - Drug Profile 173
  • bevacizumab biosimilar - Drug Profile 176
  • bevacizumab biosimilar - Drug Profile 178
  • bevacizumab biosimilar - Drug Profile 179
  • bevacizumab biosimilar - Drug Profile 180
  • bevacizumab biosimilar - Drug Profile 181
  • bevacizumab biosimilar - Drug Profile 182
  • bevacizumab biosimilar - Drug Profile 183
  • bevacizumab biosimilar - Drug Profile 184
  • bevacizumab biosimilar - Drug Profile 185
  • bevacizumab biosimilar - Drug Profile 186
  • bevacizumab biosimilar - Drug Profile 187
  • BLR-111 - Drug Profile 188
  • BLSILSB-710c - Drug Profile 189
  • BMS-986016 - Drug Profile 190
  • BVAC-C - Drug Profile 192
  • Cellular Immunotherapy for HPV Associated Cancers - Drug Profile 193
  • Cellular Immunotherapy for Oncology - Drug Profile 194
  • Cellular Immunotherapy to Target HPV-16 E6 Protein for Cancer - Drug Profile 195
  • Cellular Immunotherapy to Target HPV-16 E7 Protein for Head and Neck Cancer and Cervical Cancer - Drug Profile 197
  • CerviVax - Drug Profile 199
  • Cervlysis - Drug Profile 200
  • CIGB-300 - Drug Profile 201
  • CMD-004 - Drug Profile 203
  • COTI-2 - Drug Profile 204
  • crocetin - Drug Profile 212
  • dianhydrogalactitol - Drug Profile 213
  • docetaxel - Drug Profile 225
  • DPXE-7 - Drug Profile 227
  • E-7046 - Drug Profile 228
  • EDA-HPVE7 - Drug Profile 229
  • EDOB-278 - Drug Profile 230
  • EF-022 - Drug Profile 231
  • EG-HPV - Drug Profile 232
  • Enzymes to Inhibit HPV E7 for Human Papillomavirus Related Cervical Cancer - Drug Profile 233
  • ET-1502 - Drug Profile 234
  • ETBX-041 - Drug Profile 235
  • etirinotecan pegol - Drug Profile 236
  • GM-102 - Drug Profile 242
  • GSK-2256098 - Drug Profile 244
  • GSK-2849330 - Drug Profile 246
  • GTL-001 - Drug Profile 247
  • GTL-002 - Drug Profile 250
  • GX-I7 - Drug Profile 251
  • HPViNT - Drug Profile 252
  • human papillomavirus vaccine - Drug Profile 253
  • human papillomavirus vaccine - Drug Profile 254
  • human papillomavirus vaccine - Drug Profile 255
  • human papillomavirus vaccine - Drug Profile 256
  • human papillomavirus vaccine [types 6, 11, 16, 18] biosimilar - Drug Profile 257
  • ISA-101 - Drug Profile 258
  • JNJ-61610588 - Drug Profile 261
  • Kevetrin - Drug Profile 262
  • KITE-439 - Drug Profile 273
  • LN-145 - Drug Profile 274
  • Lovaxin S - Drug Profile 276
  • Monoclonal Antibody Conjugate to Target CD40 for Cervical, Head And Neck Cancer - Drug Profile 277
  • naltrexone hydrochloride - Drug Profile 278
  • nimotuzumab - Drug Profile 281
  • nintedanib - Drug Profile 285
  • NIT-02 - Drug Profile 295
  • nivolumab - Drug Profile 296
  • NP-001 - Drug Profile 330
  • NTO-1151 - Drug Profile 331
  • Oncoprev - Drug Profile 333
  • OTAC-DCtag - Drug Profile 334
  • paclitaxel - Drug Profile 335
  • paclitaxel - Drug Profile 337
  • paclitaxel albumin free - Drug Profile 341
  • PDS-0101 - Drug Profile 342
  • pembrolizumab - Drug Profile 344
  • PF-04518600 - Drug Profile 382
  • phosphoethanolamine - Drug Profile 384
  • RA-190 - Drug Profile 385
  • Recombinant Protein to Inhibit NFKB for Cervical Cancer and Breast Cancer - Drug Profile 386
  • RG-7876 - Drug Profile 387
  • RX-3117 - Drug Profile 388
  • S-009131 - Drug Profile 393
  • SAR-408701 - Drug Profile 394
  • SEL-701 - Drug Profile 395
  • selinexor - Drug Profile 396
  • SGN-LIV1A - Drug Profile 415
  • sirolimus albumin-bound - Drug Profile 417
  • Small molecule to Inhibit Bcl-x Protein and MCL-1 for Oncology - Drug Profile 419
  • STP-900 - Drug Profile 420
  • Subunit Vaccine for HPV Associated Cervical Cancer - Drug Profile 421
  • Synthetic Peptides to Inhibit Bcl-x and MCL-1 for Oncology - Drug Profile 422
  • TA-CIN - Drug Profile 423
  • TAS-114 - Drug Profile 424
  • Tenacinol - Drug Profile 425
  • tisotumab vedotin - Drug Profile 426
  • TT-12 - Drug Profile 428
  • TVGV-1 - Drug Profile 429
  • utomilumab - Drug Profile 430
  • Vaccine for HPV Associated Cancers - Drug Profile 432
  • Vaccine for HPV Associated Cervical Cancer - Drug Profile 433
  • Vaccine for HPV Associated Cervical Cancer - Drug Profile 434
  • Vaccine for HPV Associated Cervical Cancer - Drug Profile 435
  • Vaccine for Human papillomavirus Associated Cervical Cancer - Drug Profile 436
  • Vaccine to Target HIG2, VEGFR-1 and VEGFR-2 for Ovarian Cancer and Cervical Cancer - Drug Profile 437
  • Vaccine to Target HPV E7 Protein for Cervical Cancer - Drug Profile 438
  • Vaccine to Target HPV Minor Capsid Protein L2 for Cervical Cancer - Drug Profile 439
  • Vaccine to Target IL-2 and E7 Protein for Cervical Cancer and Oropharyngeal Cancer - Drug Profile 440
  • Vicoryx - Drug Profile 441
  • Vvax-001 - Drug Profile 442
  • Cervical Cancer - Dormant Projects 443
  • Cervical Cancer - Discontinued Products 450
  • Cervical Cancer - Product Development Milestones 451
  • Featured News & Press Releases 451
  • Appendix 463
  • Methodology 463
  • Coverage 463
  • Secondary Research 463
  • Primary Research 463
  • Expert Panel Validation 463
  • Contact Us 463
  • Disclaimer 46

List of Tables

  • Number of Products under Development for Cervical Cancer, H2 2016 21
  • Number of Products under Development for Cervical Cancer - Comparative Analysis, H2 2016 22
  • Number of Products under Development by Companies, H2 2016 23
  • Number of Products under Development by Companies, H2 2016 (Contd..1) 24
  • Number of Products under Development by Companies, H2 2016 (Contd..2) 25
  • Number of Products under Development by Companies, H2 2016 (Contd..3) 26
  • Number of Products under Development by Companies, H2 2016 (Contd..4) 27
  • Number of Products under Development by Companies, H2 2016 (Contd..5) 28
  • Number of Products under Investigation by Universities/Institutes, H2 2016 29
  • Comparative Analysis by Late Stage Development, H2 2016 30
  • Comparative Analysis by Clinical Stage Development, H2 2016 31
  • Comparative Analysis by Early Stage Development, H2 2016 32
  • Comparative Analysis by Unknown Stage Development, H2 2016 33
  • Products under Development by Companies, H2 2016 34
  • Products under Development by Companies, H2 2016 (Contd..1) 35
  • Products under Development by Companies, H2 2016 (Contd..2) 36
  • Products under Development by Companies, H2 2016 (Contd..3) 37
  • Products under Development by Companies, H2 2016 (Contd..4) 38
  • Products under Development by Companies, H2 2016 (Contd..5) 39
  • Products under Development by Companies, H2 2016 (Contd..6) 40
  • Products under Investigation by Universities/Institutes, H2 2016 41
  • Cervical Cancer - Pipeline by Abion Inc, H2 2016 42
  • Cervical Cancer - Pipeline by Admedus Ltd, H2 2016 43
  • Cervical Cancer - Pipeline by Advaxis Inc, H2 2016 44
  • Cervical Cancer - Pipeline by Advenchen Laboratories LLC, H2 2016 45
  • Cervical Cancer - Pipeline by Antigen Express Inc, H2 2016 46
  • Cervical Cancer - Pipeline by Arbor Vita Corp, H2 2016 47
  • Cervical Cancer - Pipeline by ArQule Inc, H2 2016 48
  • Cervical Cancer - Pipeline by AstraZeneca Plc, H2 2016 49
  • Cervical Cancer - Pipeline by AVEO Pharmaceuticals Inc, H2 2016 50
  • Cervical Cancer - Pipeline by Azaya Therapeutics Inc, H2 2016 51
  • Cervical Cancer - Pipeline by Bioleaders Corporation, H2 2016 52
  • Cervical Cancer - Pipeline by Biomics Biotechnologies Co Ltd, H2 2016 53
  • Cervical Cancer - Pipeline by Blirt SA, H2 2016 54
  • Cervical Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2016 55
  • Cervical Cancer - Pipeline by Bristol-Myers Squibb Company, H2 2016 56
  • Cervical Cancer - Pipeline by Cancer Research Technology Ltd, H2 2016 57
  • Cervical Cancer - Pipeline by Cell Medica Ltd, H2 2016 58
  • Cervical Cancer - Pipeline by Cellceutix Corp, H2 2016 59
  • Cervical Cancer - Pipeline by Coherus BioSciences Inc, H2 2016 60
  • Cervical Cancer - Pipeline by Critical Outcome Technologies Inc, H2 2016 61
  • Cervical Cancer - Pipeline by CZ BioMed Corp, H2 2016 62
  • Cervical Cancer - Pipeline by DelMar Pharmaceuticals, Inc., H2 2016 63
  • Cervical Cancer - Pipeline by Dr. Reddy's Laboratories Ltd, H2 2016 64
  • Cervical Cancer - Pipeline by EirGenix Inc., H2 2016 65
  • Cervical Cancer - Pipeline by Eisai Co Ltd, H2 2016 66
  • Cervical Cancer - Pipeline by Etubics Corp, H2 2016 67
  • Cervical Cancer - Pipeline by Eureka Therapeutics Inc, H2 2016 68
  • Cervical Cancer - Pipeline by EyeGene Inc, H2 2016 69
  • Cervical Cancer - Pipeline by F. Hoffmann-La Roche Ltd, H2 2016 70
  • Cervical Cancer - Pipeline by Formune SL, H2 2016 71
  • Cervical Cancer - Pipeline by GamaMabs Pharma SA, H2 2016 72
  • Cervical Cancer - Pipeline by Gene Techno Science Co Ltd, H2 2016 73
  • Cervical Cancer - Pipeline by Genexine Inc, H2 2016 74
  • Cervical Cancer - Pipeline by Genmab A/S, H2 2016 75
  • Cervical Cancer - Pipeline by Genor BioPharma Co Ltd, H2 2016 76
  • Cervical Cancer - Pipeline by Genticel S.A., H2 2016 77
  • Cervical Cancer - Pipeline by GlaxoSmithKline Plc, H2 2016 78
  • Cervical Cancer - Pipeline by Immune Therapeutics, Inc., H2 2016 79
  • Cervical Cancer - Pipeline by Immunovaccine Inc, H2 2016 80
  • Cervical Cancer - Pipeline by INSYS Therapeutics Inc, H2 2016 81
  • Cervical Cancer - Pipeline by ISA Pharmaceuticals BV, H2 2016 82
  • Cervical Cancer - Pipeline by Johnson & Johnson, H2 2016 83
  • Cervical Cancer - Pipeline by Karyopharm Therapeutics Inc, H2 2016 84
  • Cervical Cancer - Pipeline by Kite Pharma Inc, H2 2016 85
  • Cervical Cancer - Pipeline by LondonPharma Ltd, H2 2016 86
  • Cervical Cancer - Pipeline by Mabion SA, H2 2016 87
  • Cervical Cancer - Pipeline by Merck & Co Inc, H2 2016 88
  • Cervical Cancer - Pipeline by Mycenax Biotech Inc, H2 2016 89
  • Cervical Cancer - Pipeline by Nanotherapeutics Inc, H2 2016 90
  • Cervical Cancer - Pipeline by Nektar Therapeutics, H2 2016 91
  • Cervical Cancer - Pipeline by Oncobiologics Inc, H2 2016 92
  • Cervical Cancer - Pipeline by Ono Pharmaceutical Co Ltd, H2 2016 93
  • Cervical Cancer - Pipeline by Oryx GmbH & Co KG, H2 2016 94
  • Cervical Cancer - Pipeline by PDS Biotechnology Corp, H2 2016 95
  • Cervical Cancer - Pipeline by Pfizer Inc, H2 2016 96
  • Cervical Cancer - Pipeline by Psicofarma SA de CV, H2 2016 97
  • Cervical Cancer - Pipeline by Rexahn Pharmaceuticals Inc, H2 2016 98
  • Cervical Cancer - Pipeline by Richter Gedeon Nyrt, H2 2016 99
  • Cervical Cancer - Pipeline by Samyang Holdings Corp, H2 2016 100
  • Cervical Cancer - Pipeline by Sanofi, H2 2016 101
  • Cervical Cancer - Pipeline by Savoy Pharmaceuticals, Inc., H2 2016 102
  • Cervical Cancer - Pipeline by Seattle Genetics Inc, H2 2016 103
  • Cervical Cancer - Pipeline by Selecta Biosciences Inc, H2 2016 104
  • Cervical Cancer - Pipeline by Shantha Biotechnics Ltd, H2 2016 105
  • Cervical Cancer - Pipeline by Sirnaomics Inc, H2 2016 106
  • Cervical Cancer - Pipeline by Sun Pharma Advanced Research Company Ltd, H2 2016 107
  • Cervical Cancer - Pipeline by Taiho Pharmaceutical Co Ltd, H2 2016 108
  • Cervical Cancer - Pipeline by Tessa Therapeutics Pte Ltd, H2 2016 109
  • Cervical Cancer - Pipeline by Theravectys SA, H2 2016 110
  • Cervical Cancer - Pipeline by THEVAX Genetics Vaccine USA Inc, H2 2016 111
  • Cervical Cancer - Pipeline by Tomegavax Inc, H2 2016 112
  • Cervical Cancer - Pipeline by UbiVac LLC, H2 2016 113
  • Cervical Cancer - Pipeline by VLPbio, H2 2016 114
  • Cervical Cancer - Pipeline by Zeria Pharmaceutical Co Ltd, H2 2016 115
  • Cervical Cancer - Pipeline by Zydus Cadila Healthcare Ltd, H2 2016 116
  • Assessment by Monotherapy Products, H2 2016 117
  • Assessment by Combination Products, H2 2016 118
  • Number of Products by Stage and Target, H2 2016 120
  • Number of Products by Stage and Mechanism of Action, H2 2016 125
  • Number of Products by Stage and Route of Administration, H2 2016 130
  • Number of Products by Stage and Molecule Type, H2 2016 132
  • Cervical Cancer - Dormant Projects, H2 2016 451
  • Cervical Cancer - Dormant Projects (Contd..1), H2 2016 452
  • Cervical Cancer - Dormant Projects (Contd..2), H2 2016 453
  • Cervical Cancer - Dormant Projects (Contd..3), H2 2016 454
  • Cervical Cancer - Dormant Projects (Contd..4), H2 2016 455
  • Cervical Cancer - Dormant Projects (Contd..5), H2 2016 456
  • Cervical Cancer - Dormant Projects (Contd..6), H2 2016 457
  • Cervical Cancer - Discontinued Products, H2 2016 45

List of Figures

  • Number of Products under Development for Cervical Cancer, H2 2016 21
  • Number of Products under Development for Cervical Cancer - Comparative Analysis, H2 2016 22
  • Number of Products under Development by Companies, H2 2016 23
  • Number of Products under Investigation by Universities/Institutes, H2 2016 29
  • Comparative Analysis by Clinical Stage Development, H2 2016 31
  • Comparative Analysis by Early Stage Products, H2 2016 32
  • Assessment by Monotherapy Products, H2 2016 117
  • Number of Products by Top 10 Targets, H2 2016 119
  • Number of Products by Stage and Top 10 Targets, H2 2016 119
  • Number of Products by Top 10 Mechanism of Actions, H2 2016 124
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 124
  • Number of Products by Top 10 Routes of Administration, H2 2016 129
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2016 129
  • Number of Products by Top 10 Molecule Types, H2 2016 131
  • Number of Products by Stage and Top 10 Molecule Types, H2 2016 131
Back to Top